Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
复制标题
DOI：
10.1038/sj.bjc.6603026
复制
发表时间：
2006-03-27
影响因子：
8.8
通讯作者：
Brandes, AA
中科院分区：
文献类型：
--
作者：
Reni, M;Pasetto, L;Aprile, G;Cordio, S;Bonetto, E;Dell'Oro, S;Passoni, P;Piemonti, L;Fugazza, C;Luppi, G;Milandri, C;Nicoletti, R;Zerbi, A;Balzano, G;Di Carlo, V;Brandes, AA
关于胰腺癌患者挽救治疗的信息有限。在失败时，大约一半的患者表现出良好的体能状态（PS），并有可能接受进一步治疗。年龄>18岁、PS ≥ 50、既往接受过含吉西他滨化疗且无进展生存期（PFS）<12个月的转移性胰腺癌患者接受雷替曲塞（3 mg m−2）和奥沙利铂（130 mg m−2）联合治疗，每3周一次，直至进展、毒性或最多6个周期。共41例患者接受了137个周期的化疗。两种药物的剂量强度均为预期剂量的92%。>2级的主要毒性是：5名患者的中性粒细胞减少症（12%），3名患者的血小板减少症、肝脏和呕吐（7%），2名患者的疲劳（5%）。总共有10名患者（24%）产生了部分缓解，11名患者病情稳定。6个月无进展生存率为14.6%。中位生存期为5.2个月。既往PFS >6个月的患者和无胰腺定位的患者的生存期显著延长。在许多领域观察到临床相关的生活质量改善。雷替鲁明-奥沙利铂方案可能是吉西他滨耐药转移性胰腺癌的治疗机会。既往PFS间期可用于识别更有可能从挽救治疗中获益的患者。
Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS ⩾50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) <12 months received a combination of raltitrexed (3 mg m−2) and oxaliplatin (130 mg m−2) every 3 weeks until progression, toxicity, or a maximum of six cycles. A total of 41 patients received 137 cycles of chemotherapy. Dose intensity for both drugs was 92% of the intended dose. Main grade >2 toxicity was: neutropenia in five patients (12%), thrombocytopenia, liver and vomiting in three (7%), fatigue in two (5%). In total, 10 patients (24%) yielded a partial response, 11 a stable disease. Progression-free survival at 6 months was 14.6%. Median survival was 5.2 months. Survival was significantly longer in patients with previous PFS >6 months and in patients without pancreatic localisation. A clinically relevant improvement of quality of life was observed in numerous domains. Raltitrexed–oxaliplatin regimen may constitute a treatment opportunity in gemcitabine-resistant metastatic pancreatic cancer. Previous PFS interval may allow the identification of patients who are more likely to benefit from salvage treatment.
登录
查看更多内容
影响因子：
50.5
作者：
Glimelius, B;Hoffman, K;Svensson, C
通讯作者：
Svensson, C
影响因子：
51.1
作者：
Reni, M;Cordio, S;Di Carlo, V
通讯作者：
Di Carlo, V
影响因子：
8.4
作者：
Fitzsimmons, D;Johnson, CD;Tihanyi, T
通讯作者：
Tihanyi, T
影响因子：
8.8
作者：
Bramhall, SR;Schulz, J;Nemunaitis, J;Brown, PD;Baillet, M;Buckels, JAC
通讯作者：
Buckels, JAC
影响因子：
3.5
作者：
Cantore, M;Rabbi, C;Manni, A
通讯作者：
Manni, A